Novel therapy of hyperhomocysteinemia in mild cognitive impairment, Alzheimer’s disease, and other dementing disorders
- 322 Downloads
Studies have produced conflicting results assessing hyperhomocysteinemia (HYH) treatment with B vitamins in patients with normal cognition, Alzheimer’s disease and related disorders (ADRD). This study examined the effect of HYH management with L-methylfolate (LMF), methylcobalamin (MeCbl; B12), and N-acetyl-cysteine (CFLN: Cerefolin®/Cerefolin-NAC®) on cognitive decline.
Prospective, case-control study of subjects followed longitudinally.
Outpatient clinic for cognitive disorders.
116 ADRD patients (34 with HYH, 82 with No-HYH) met inclusion and exclusion criteria to participate. No study participant took B vitamins.
HYH patients received CFLN, and No-HYH patients did not.
Cognitive outcome measures included MCI Screen (memory), CERAD Drawings (constructional praxis), Ishihara Number Naming (object recognition), Trails A and B (executive function), and F-A-S test (verbal fluency). Dependent or predictor measures included demographics, functional severity, CFLN and no CFLN treatment duration, ADRD diagnosis, memantine and cholinesterase inhibitor treatment. Linear mixed effects models with covariate adjustment were used to evaluate rate of change on cognitive outcomes.
The duration of CFLN treatment, compared to an equivalent duration without CFLN treatment, significantly slowed decline in learning and memory, constructional praxis, and visual-spatial executive function (Trails B). CFLN treatment slowed cognitive decline significantly more for patients with milder baseline severity. CFLN treatment effect increased as baseline functional severity decreased. The analytical model showed that treatment duration must exceed some minimum period of at least one year to slow the rate of cognitive decline.
After covariate adjustment, HYH+CFLN significantly slowed cognitive decline compared to No-HYH+No-CFLN. Longer CFLN treatment duration, milder baseline severity, and magnitude of homocysteine reduction from baseline were all significant predictors. There are a number of factors that could account for disagreement with other clinical trials of B vitamin treatment of HYH. Moreover, CFLN is chemically distinct from commonly used B vitamins as both LMF and MeCbl are the fully reduced and bioactive functional forms; CLFN also contains the glutathione precursor, N-acetyl-cysteine. The findings of other B vitamin trials of HYH can, therefore, only partly account for treatment effects of CFLN. These findings warrant further evaluation with a randomized, placebo-controlled trial.
Key wordsHomocysteine cognitive impairment N-acetyl-cysteine L-methylfolate methylcobalamin B vitamins
- 14.Lim AS, Srivastava GP, Yu L, Chibnik LB, Xu J, Buchman AS, Schneider JA, Myers AJ, Bennett DA, De Jager PL. 24-hour rhythms of DNA methylation and their relation with rhythms of RNA expression in the human dorsolateral prefrontal cortex. PLoS Genet. 2014;10(11):e1004792.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Robinson RA, Joshi G, Huang Q, Sultana R, Baker AS, Cai J, Pierce W, St Clair DK, Markesbery WR, Butterfield DA. Proteomic analysis of brain proteins in APP/ PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer’s disease. Proteomics. 2011;11(21):4243–4256.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Shankle WR, Hara J, Rafii MS, Russell J. Impact of Hyperhomocysteinemia Treatment on Cognitive Decline due to Alzheimer’s Disease and Related Disorders. JARCP. 2013;2(4): 319–324.Google Scholar
- 27.Moustafa AA, Hewedi DH, Eissa AM et al. The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment. PLoS One. 2012;7(9):e46496.Google Scholar
- 28.Sala I, Belén Sánchez-Saudinós M, Molina-Porcel L, Lázaro E, Gich I, Clarimón J, Blanco-Vaca F, Blesa R, Gómez-Isla T, Lleó A. Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord. 2008;26(6):506–512.CrossRefPubMedGoogle Scholar
- 29.Doets EL, Ueland PM, Tell GS, Vollset SE, Nygård OK, Van’t Veer P, de Groot LC, Nurk E, Refsum H, Smith AD, Eussen SJ. Interactions between plasma concentrations of folate and markers of vitamin B(12) status with cognitive performance in elderly people not exposed to folic acid fortification: the Hordaland Health Study. Br J Nutr. 2014;111(6):1085–1095CrossRefPubMedGoogle Scholar
- 30.Miller JW, Garrod MG, Allen LH, Haan MN, Green R. Metabolic evidence of vitamin B-12 deficiency, including high homocysteine and methylmalonic acid and low holotranscobalamin, is more pronounced in older adults with elevated plasma folate. Am J Clin Nutr. 2009 Dec;90(6):1586–92.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Rabaneda LG, Carrasco M, Lopez-Toledano MA, Murillo-Carretero M, Ruiz FA, Estrada C, Castro C. Homocysteine inhibits proliferation of neuronal precursors in the mouse adult brain by impairing the basic fibroblast growth factor signaling cascade and reducing extracellular regulated kinase 1/2-dependent cyclin E expression. FASEB J. 2008;22(11):3823–3835.CrossRefPubMedGoogle Scholar
- 36.Rideau Batista Novais A, Guiramand J, Cohen-Solal C, Crouzin N, de Jesus Ferreira MC, Vignes M, Barbanel G, Cambonie G. N-acetyl-cysteine prevents pyramidal cell disarray and reelin-immunoreactive neuron deficiency in CA3 after prenatal immune challenge in rats. Pediatr Res. 2013;73(6):750–755.CrossRefPubMedGoogle Scholar
- 37.Otte DM, Sommersberg B, Kudin A, Guerrero C, Albayram O, Filiou MD, Frisch P, Yilmaz O, Drews E, Turck CW, Bilkei-Gorzó A, Kunz WS, Beck H, Zimmer A. N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology. 2011;36(11):2233–2243.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, Mäkelä M, Oinas M, Paetau A, Scheltens P, van Straaten EC, Sulkava R, Solomon A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a populationbased autopsy study. Brain. 2013;136(Pt 9):2707–2716.CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D’Anselmi F, Coluccia P, Calamandrei G, Scarpa S. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice.31. Mol Cell Neurosci. 2008;37(4):731–746.CrossRefPubMedGoogle Scholar